TransMedics Group, Inc. $TMDX Shares Sold by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP reduced its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 66.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 38,390 shares of the company’s stock after selling 75,481 shares during the quarter. Divisadero Street Capital Management LP’s holdings in TransMedics Group were worth $5,145,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Intech Investment Management LLC increased its stake in shares of TransMedics Group by 28.9% in the second quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock worth $4,608,000 after acquiring an additional 7,713 shares during the last quarter. Valmark Advisers Inc. grew its stake in TransMedics Group by 34.6% in the second quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock valued at $1,301,000 after purchasing an additional 2,496 shares in the last quarter. Raymond James Financial Inc. increased its position in TransMedics Group by 135.8% in the 1st quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock worth $9,782,000 after purchasing an additional 83,722 shares during the last quarter. Intrust Bank NA acquired a new position in TransMedics Group in the 2nd quarter worth about $747,000. Finally, Northern Trust Corp raised its stake in shares of TransMedics Group by 2.1% during the 1st quarter. Northern Trust Corp now owns 361,963 shares of the company’s stock worth $24,353,000 after purchasing an additional 7,341 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 1.5%

Shares of TMDX stock opened at $136.51 on Monday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $156.00. The company has a market cap of $4.66 billion, a PE ratio of 55.27 and a beta of 2.06. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The business’s 50 day moving average is $125.00 and its two-hundred day moving average is $122.85.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same period in the prior year, the firm earned $0.12 EPS. TransMedics Group’s quarterly revenue was up 32.2% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TMDX shares. Jefferies Financial Group started coverage on TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Morgan Stanley lifted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a report on Thursday, October 30th. Finally, Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Insider Activity

In related news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 4,142 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the sale, the director owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. The trade was a 59.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 13,062 shares of company stock worth $1,797,634 in the last 90 days. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.